Optimization of cardiac metabolism in heart failure.

abstract：:Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease worldwide. This is primarily driven by the global epidemic of obesity and diabetes as well as the aging of the general population. Most of the epidemiology data of NAFLD for North America are published from stud...

journal_title：Current pharmaceutical design

authors： Arshad T,Golabi P,Henry L,Younossi ZM

更新日期：2020-01-01 00:00:00

abstract：:Nesfatin-1, derived from the precursor NEFA/nucleobindin2 (NUCB2), was initially identified as a feeding-suppressing neuropeptide, acting at central (mainly, hypothalamic) levels in a leptin-independent manner. However, recent experimental evidence strongly suggests that, rather than being a simple anorectic hypothala...

journal_title：Current pharmaceutical design

authors： García-Galiano D,Tena-Sempere M

更新日期：2013-01-01 00:00:00

abstract：:Glucocorticoids are the first line medication used in the therapy of many severe inflammatory disorders. They exert their activity through binding to the glucocorticoid receptor, a ligand-dependent transcription factor, and result in either activation or repression of a large set of glucocorticoid responsive genes. Th...

journal_title：Current pharmaceutical design

authors： Schulz M,Eggert M

更新日期：2004-01-01 00:00:00

abstract：:Recent advances in the fabrication, characterization and application of micro- and nano-particles that possess a non-uniform internal structure are reviewed. The particle structures include core-shell particles, particles with multiple cores or a multi-layered structure, porous particles with both regular and random p...

journal_title：Current pharmaceutical design

authors： Čejková J,Štêpánek F

更新日期：2013-01-01 00:00:00

abstract：:Topiramate is one of the currently most promising compounds in the field of addiction medicine. This paper discusses its potential utility related to a phase model of addiction development, focusing on the assumption that addiction is a continuous process involving different neurobiological pathways, depending on the ...

journal_title：Current pharmaceutical design

authors： Thorens G,Billieux J,Manghi R,Khan R,Khazaal Y,Zullino DF

更新日期：2011-01-01 00:00:00

abstract：:Adenosine triphosphate (ATP) synthase produces ATP in cells and is found on the inner membrane of mitochondria or the cell plasma membrane (ectopic ATP synthase). Here, we summarize the functions of ectopic ATP synthase in vascular endothelial cells (ECs). Ectopic ATP synthase is involved in adenosine metabolism on th...

journal_title：Current pharmaceutical design

authors： Fu Y,Zhu Y

更新日期：2010-01-01 00:00:00

abstract：:First generation drug-eluting stents (DES) have significantly improved the treatment options for patients with symptomatic coronary artery disease by decreasing rates of acute vessel closure and restenosis after percutaneous coronary revascularization procedures. However, early enthusiasm was temperd by reports of lat...

journal_title：Current pharmaceutical design

authors： Vorpahl M,Yazdani SK,Nakano M,Ladich E,Kolodgie FD,Finn AV,Virmani R

更新日期：2010-01-01 00:00:00

abstract：:The pharmacophore concept is central to the rational drug design and discovery process. Traditionally, a pharmacophore is defined as a specific three-dimensional (3D) arrangement of chemical functional groups found in active molecules, which are characteristic of a certain pharmacological class of compounds. Herein, b...

journal_title：Current pharmaceutical design

authors： Tropsha A,Zheng W

更新日期：2001-05-01 00:00:00

abstract：:Non-alcoholic fatty liver disease (NAFLD) includes liver diseases ranging from simple steatosis to progressive forms characterized by high rates of complications and mortality, namely fibrosis, cirrhosis and hepatocellular carcinoma. Identification of patients with simple steatosis who will evolve to a more severe liv...

journal_title：Current pharmaceutical design

authors： Lombardi R,Fargion S,Fracanzani AL

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:From the evidence of failed injection-based growth factor therapies, it has been proposed that a naturally triggered uninterrupted blood circulation of the growth factors would be superior. OBJECTIVE:We seek to stimulate discussions and more research about the possibility of using the already available grow...

journal_title：Current pharmaceutical design

authors： Muresanu C,Somasundaram SG,Vissarionov SV,Gavryushova LV,Nikolenko VN,Mikhaleva LM,Kirkland CE,Aliev G

更新日期：2020-10-18 00:00:00

abstract：:The rapid advancement of computer architectures and development of mathematical algorithms offer a unique opportunity to leverage the simulation of macromolecular systems at physiologically relevant timescales. Herein, we discuss the impact of diverse structure-based and ligand-based molecular modeling techniques in d...

journal_title：Current pharmaceutical design

authors： Samanta PN,Kar S,Leszczynski J

更新日期：2019-01-01 00:00:00

abstract：:BMS-378806 is a prototype of a new class of small molecule HIV-1 inhibitors that blocks viral attachment to cells. This compound exhibits potent inhibitory activity against a panel of HIV-1 laboratory and clinical isolates (M- and T-tropic), selective for HIV-1 and inactive against HIV-2, SIV and a panel of other viru...

journal_title：Current pharmaceutical design

authors： Wang HG,Williams RE,Lin PF

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide directly related to the progressive increase in overweight and obesity. The accumulation of lipids in patients with NAFLD contributes to the development of insulin resistance, inflammatory response a...

journal_title：Current pharmaceutical design

authors： Tejada S,Capó X,Mascaró CM,Monserrat-Mesquida M,Quetglas-Llabrés MM,Pons A,Tur JA,Sureda A

更新日期：2020-04-17 00:00:00

abstract：:Immunotoxins (ITs) are protein-based drugs combining a target-specific binding domain (usually derived from an antibody) and a cytotoxic domain to kill target cells. They are among the most promising new therapeutic tools to fight cancer, and several clinical trials have been completed with encouraging results. Althou...

journal_title：Current pharmaceutical design

authors： Hetzel C,Bachran C,Tur MK,Fuchs H,Stöcker M

更新日期：2009-01-01 00:00:00

abstract：:Urological cancer refers to cancer in organs of the urinary system and the male reproductive system. It mainly includes prostate cancer, bladder cancer, renal cancer, etc., seriously threatening patients' survival. Although there are many advances in the treatment of urological cancer, approved targeted therapies ofte...

journal_title：Current pharmaceutical design

authors： Liu Q,Gu J,Zhang E,He L,Yuan ZX

更新日期：2020-01-01 00:00:00

abstract：:Apoptosis is a regulated process leading to cell death, which is implicated both in normal development and in various pathologies including heart failure, stroke and neurodegenerative diseases. Caspase-3, a key enzyme of the apoptotic pathway, is considered as a major target for the treatment of abnormal cell death. M...

journal_title：Current pharmaceutical design

authors： Seaborn T,Masmoudi-Kouli O,Fournier A,Vaudry H,Vaudry D

更新日期：2011-01-01 00:00:00

abstract：:Cardiac arrhythmias remain a major source of morbidity and mortality in developed countries. Antiarrhythmic drug therapy was traditionally the mainstay of cardiac arrhythmia treatment; however, drug therapy of cardiac arrhythmias has been plagued by incomplete efficacy and by potentially serious adverse reactions, of ...

journal_title：Current pharmaceutical design

authors： Hesketh JC,Herrera D,Zicha S,Nattel S

更新日期：2005-01-01 00:00:00

abstract：:Subjects affected by ischemic heart disease with non-obstructive coronary arteries constitute a population that has received increasing attention over the past two decades. Since the first studies with coronary angiography, female patients have been reported to have non-obstructive coronary artery disease more frequen...

journal_title：Current pharmaceutical design

authors： Bergami M,Scarpone M,Cenko E,Varotti E,Amaduzzi PL,Manfrini O

更新日期：2020-10-12 00:00:00

abstract：:It is well known that heat shock proteins (HSPs) are induced by various stressors in order to confer protection against such stressors. Since stressor-induced tissue damage is involved in various diseases, especially gastrointestinal diseases, such as gastric ulcer, it has been thought that HSPs are protective against...

journal_title：Current pharmaceutical design

authors： Mizushima T

更新日期：2010-01-01 00:00:00

abstract：:Separating emotions from cognition seems impossible in everyday experiences of a human being. Emotional processes have an impact on the ability of planning and solving problems, or decision-making skills. They are a valuable source of information about ourselves, our partners in interactions and the surrounding world....

journal_title：Current pharmaceutical design

authors： Talarowska M,Galecki P

更新日期：2016-01-01 00:00:00

abstract：:The development of targeted therapy drugs acting on tumor growth and progression is greatly expanding these last years. Among them kinase inhibitors have a prominent position and have demonstrated efficacy and clinical benefits in solid and hematologic malignancies. Compared to conventional systemic cytotoxic chemothe...

journal_title：Current pharmaceutical design

authors： Levade M,Severin S,Gratacap MP,Ysebaert L,Payrastre B

更新日期：2016-01-01 00:00:00

abstract：:Control of GABA neurotransmission at the pre-synaptic site occurs substantially through the activation of the glutamic acid decarboxylase (GAD) enzymes GAD65 and GAD67. Concentrations of GAD65 and GAD67 are controlled either by transcription or by mRNA splicing and importantly the activities of these key enzymes are r...

journal_title：Current pharmaceutical design

authors： Modi JP,Prentice H,Wu JY

更新日期：2015-01-01 00:00:00

abstract：:Drug discovery is generally considered as a costly affair and it takes approximately 15 years to reach a new chemical entity into the market. Among the recent potent drug molecules with most effective pharmacological properties, very few reached for Phase I clinical trial in humans. Unfortunately, the historical avera...

journal_title：Current pharmaceutical design

authors： Paudwal G,Rawat N,Gupta R,Baldi A,Singh G,Gupta PN

更新日期：2019-01-01 00:00:00

abstract：:The pivotal role of leptin in regulating body weight and energy homeostasis is very well established. More recently, leptin also emerged as an important regulator of T-cell-dependent immunity. Reduced leptin levels, as observed during periods of starvation, correlate with an impaired cellular immune response, whereby ...

journal_title：Current pharmaceutical design

authors： Peelman F,Iserentant H,Eyckerman S,Zabeau L,Tavernier J

更新日期：2005-01-01 00:00:00

abstract：:α-Synuclein aggregation is centrally implicated in Parkinson's disease (PD). It involves multi-step nucleated polymerization process via the formation of dimers, soluble toxic oligomers and insoluble fibrils. In the present study, we synthesized a novel compound viz., Curcumin-glucoside (Curc-gluc), a modified form of...

journal_title：Current pharmaceutical design

authors： Gadad BS,Subramanya PK,Pullabhatla S,Shantharam IS,Rao KS

更新日期：2012-01-01 00:00:00

abstract：:P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization. Multiple lines of evidence suggest that the level of on-treatment platelet reactivity inhibition with P2Y12 ADP re...

journal_title：Current pharmaceutical design

authors： Laine M,Camoin-Jau L,Bessereau J,Sébastien A,Paganelli F,Bonello L

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Oxidative stress and inflammation are key parameters in developing metabolic disorders. Hence, antioxidant intake might be an appropriate approach. Several studies have evaluated the effect of coenzyme Q10 (CoQ10) supplementation on lipid profile among patients with metabolic diseases, though f...

journal_title：Current pharmaceutical design

authors： Sharifi N,Tabrizi R,Moosazadeh M,Mirhosseini N,Lankarani KB,Akbari M,Chamani M,Kolahdooz F,Asemi Z

更新日期：2018-01-01 00:00:00

abstract：:This manuscript provides an overview for analysts, medical and scientific investigators, and laboratory administrators, the range of factors that should be considered to implement best practice forensic toxicology. These include laboratory influence over the collection of specimens, their proper transport and chain-of...

journal_title：Current pharmaceutical design

authors： Drummer OH

更新日期：2017-01-01 00:00:00

abstract：:In order to productively infect a host, viruses must enter the cell and force host cell replication mechanisms to produce new infectious virus particles. The success of this process unfortunately results in disease progression and, in the case of infection with many viral species, may cause mortality. The discoveries ...

journal_title：Current pharmaceutical design

authors： Skoreński M,Sieńczyk M

更新日期：2013-01-01 00:00:00

abstract：:Ischaemic stroke of the brain accounts for about one third of all deaths in industrialized countries. Many of the patients who survive are severily impaired. Thus, there is an enormous need for pharmacotherapy for the treatment of ischaemic stroke. Why is such a treatment not available yet? Are the pathophysiological ...

journal_title：Current pharmaceutical design

authors： Weiser T

更新日期：2002-01-01 00:00:00